Bristol-Myers Squibb Company
NYSE: BMY
$49.41
+$0.39 (+0.8%)
Closing Price on September 20, 2024
BMY Articles
We were screening options activity today and something came up that where bets had significantly grown from our prior coverage. Earlier this year we covered some strange biotech options activity...
Published:
Last Updated:
According to Reuters, Morgan Stanley (MS) plans to start a wealth management business in India. Reuters writes that Alan Greenspan said that US economic growth is slowing. Reuters writes that SAP...
Published:
According to Reuters, Microsoft (MSFT) launched its Halo 3 game which is essential to driving Xbox sales. Reuters writes that the UAW struck GM (GM) as contract negotiations failed. Reuters reportst...
Published:
Shares of Imclone Systems Inc. (NASDAQ:IMCL) are screaming higher this morning on it meeting its primary endpoint of increasing survival in its Phase III lung cancer studies. Imclone and partner...
Published:
Last Updated:
A new medical study shows that people who take statins, cholesterol-lowering drugs, appear to be less likely to develope Alzheimer’s, one of the most damaging and fastest growing diseases....
Published:
ADNEXUS THERAPEUTICS, INC. has filed to come public via an IPO with the filed amount to sell up to $86,250,000 in common stock. Adnexus has taken the proposed ADNX ticker on NASDAQ. Lehman and...
Published:
Stock Tickers: ABI, BBSI, BMY, CAP, CLUB, CVX, FCBP, GM, IPG, OMC, MIG, PER, PIR, SKH, SMSI, TRLG ABI raised to Outperform at Baird.BBSI raised to Strong Buy at JMP Securities.BMY raised to...
Published:
As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a bit of a mixed bag. GlaxoSmithkline (GSK) saw the lagest increase, but its short...
Published:
According to Reuters, Microsoft (MSFT) will alter its Vista operating system so that it works better with Google (GOOG) and other companies that have search functions for the desktop. Reuters writes...
Published:
(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.(BAY) Bayer raised guidance on Schering...
Published:
Some sectors showed mixed results in the short selling, but the Big Pharma and medical instruments and related companies saw an increased activity in short selling in May versus April. Below is the...
Published: